Replies to post #33739 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Of course if you wanted to simply use PFS and OS as the primary and secondary endpoints for DCVax-L + CI combination trials, you could simply use the extracted tumors to make the lysate, but I think the thought is using the same patient profiles used previously for the CI trials which used ORR, but designing L in there as well as the pretreatment and concurrent combinational therapy.

ORR achieves faster approval.

Just musing while we await more data.